Record revenue of approximately $31.8 - $32.0 million for full-year 2025 and approximately $9.0 - $9.2 million for the three months ended December 31, 2025 Revenue growth of approximately 26% over full-year 2024Cash, cash equivalents, and marketable securities (“Total Cash”) balance of approximately $11.6 million as of December 31, 2025 ROCKAWAY, N.J., Jan. 20, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today provided sele ...

Company Overview - electroCore is a publicly traded neuromodulation company listed on NASDAQ under the symbol ECOR, focusing on non-invasive vagus nerve stimulation devices [3] - The company was founded in 2006 and has developed into a multi-indication business with 7 FDA authorizations for headache treatments [5] Product and Service Channels - The company operates across three main channels: prescription medical devices for headache and migraine, the Truvaga direct-to-consumer wellness brand, and a specialized military and government division featuring the ruggedized TAC-STIM product [4] - The nVNS platform delivers a two-minute therapy session aimed at rebalancing the autonomic nervous system [3] Market and Clientele - electroCore serves major customers including the U.S. Department of Veterans Affairs and the U.K.'s National Health Service, indicating a strong foothold in both governmental and healthcare sectors [5]

ROCKAWAY, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced the publication of a peer reviewed paper titled “Non-Invasive Transcutaneous Vagal Nerve Stimulation Enhances Mood, Task Performance, and Learning in a High-Stress Military Training Environment” which will be presented at the Applied Human Factors and Ergonomics (AHFE2025) Conference on December 8, 2025. The paper presents results from the l ...

Core Insights - electroCore, Inc. is participating in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025, in New York [1] - The company will host one-on-one meetings throughout the day for investors [1][2] Company Overview - electroCore, Inc. is a bioelectronic technology company focused on improving health and quality of life through non-invasive bioelectronic technologies [3] - The company's leading products include gammaCore, a non-invasive vagus nerve stimulation device for chronic pain, and Quell Fibromyalgia [3] - Additionally, electroCore offers handheld products like Truvaga and TAC-STIM, which utilize bioelectronic technologies for general wellness and human performance [3]

Financial Data and Key Metrics Changes - In Q3 2025, revenue reached a record $8.7 million, up 33% year over year and 18% sequentially [17] - Gross margins improved to 86%, up from 84% in the previous year [17] - GAAP net loss was $3.4 million, or a loss of $0.40 per share, compared to a net loss of $2.5 million, or a loss of $0.31 per share in Q3 2024 [28] - Cash balance as of September 30, 2025, was approximately $13.2 million, compared to $12.2 million at the end of 2024 [29] Business Line Data and Key Metrics Changes - Prescription device revenue grew 19% year over year to $6.8 million, driven by gammaCore and Quell sales in the VA hospital system [17] - Health and wellness product revenue reached $1.9 million, a 54% increase sequentially and 121% year on year [18] - Truvaga revenue grew 18% sequentially and 79% year on year, excluding a one-time $500,000 order for a clinical trial [19] Market Data and Key Metrics Changes - As of September 30, 2025, 195 VA hospital facilities purchased prescription gammaCore products, up from 166 a year ago [17] - The VA hospital system remains the largest customer, with significant growth opportunities identified in the fibromyalgia patient segment [18] Company Strategy and Development Direction - The company is focusing on three strategic pivots: the Neurometrics acquisition, strengthening the VA channel, and developing the wellness division [9][10][11] - The acquisition of Neurometrics has exceeded revenue expectations and is integrated into the VA hospital channel [23] - The company aims to broaden its product range and diversify revenue streams to enhance long-term shareholder value [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in prioritizing growth over immediate profitability, with a revised timeline for achieving positive adjusted EBITDA in the second half of 2026 [22] - The company is navigating external macroeconomic challenges while maintaining a focus on expanding its market presence [11][12] Other Important Information - The company is facing a patent infringement dispute with a European company, which is currently in litigation [51] - A royalty-based arrangement has been established for commercialization in China, with no capital investment required from the company [13][43] Q&A Session Summary Question: Can you remind us what channels Neurometrics was selling into before the acquisition? - The prescription Quell for fibromyalgia was sold in four or five VA hospitals off contract through open market access prior to the acquisition [36] Question: Can you give us any further color on the $500,000 Truvaga sale for a clinical trial? - It's one clinical trial being run in long COVID subjects, and details are limited as it is investigator-initiated [36] Question: Talk about the next-gen mobile app that you're working on. - The next update of the app will be Truvaga Plus only and will not be set up to work with gammaCore or Quell [37] Question: What is being done to combat the copycat marketing vagus nerve stimulation devices? - The company is in litigation with a European company for patent infringement and is focusing on winning the case [51] Question: How meaningful is the market opportunity in China? - The Chinese investor plans to commercialize the technology in China as a prescription medical device, with royalties paid to the company [43]

Core Insights - electroCore, Inc. reported net sales of $8.7 million for Q3 2025, a 33% increase compared to Q3 2024, and year-to-date net sales of $22.8 million, reflecting a 26% increase compared to the first nine months of 2024 [1][3][8] - The company has increased its revenue guidance for the full year 2025 to a range of $31.5 million to $32.5 million, driven by strong sales growth in the VA market for its prescription products [2][14] Financial Performance - For Q3 2025, net sales were $8.7 million, up from $6.6 million in Q3 2024, with a gross profit of $7.5 million, representing an 86% gross margin compared to 84% in the previous year [3][4][10] - Prescription device sales increased by 19% year-over-year, while health and wellness products saw a significant growth of 121% in the same period [4][8] - Total operating expenses for Q3 2025 were approximately $10.4 million, up from $8.1 million in Q3 2024, with selling, general, and administrative expenses rising to $9.7 million [6][7] Cash Position - As of September 30, 2025, total cash, including cash equivalents and marketable securities, was $13.2 million, an increase from $12.2 million at the end of 2024 [1][13][22] Loss and Adjusted EBITDA - The net loss for Q3 2025 was $3.4 million, or $0.40 per share, compared to a net loss of $2.5 million, or $0.31 per share, in Q3 2024 [10][20] - Adjusted EBITDA net loss for Q3 2025 was $2.0 million, slightly improved from a loss of $2.1 million in Q3 2024 [11][26] Future Outlook - The company anticipates reaching $12.0 million in quarterly revenue and achieving its first quarter of positive adjusted EBITDA in the second half of 2026 [14]

Core Insights - electroCore, Inc. will report its financial results for Q3 2025 on November 5, 2025, after market close [1] - A webinar will be held at 4:30 PM EST on the same day to discuss the results and answer investor questions [1] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through non-invasive bioelectronic technologies [2] - The company's leading products include gammaCore, a non-invasive vagus nerve stimulation device, and Quell neurostimulator, both aimed at treating chronic pain syndromes [2] - Additionally, electroCore offers Truvaga and TAC-STIM products for general wellness and human performance enhancement [2]

Core Insights - electroCore, Inc. announced a peer-reviewed study demonstrating the effectiveness of gammaCore® non-invasive vagus nerve stimulation (nVNS) in reducing persistent symptoms associated with mild traumatic brain injury (mTBI) [1][2] - The study found that adjunctive use of gammaCore with standard care led to significant improvements in multiple domains of the Neurobehavioral Symptom Inventory (NSI) [2][4] - Approximately 34% of patients reported meaningful improvement in at least half of their persistent symptoms, with significant reductions observed in 16 of 22 symptom categories [8] Study Details - The study included 102 patients with persistent symptoms following mTBI, showing improvements in both early and late treatment groups [3][8] - No device-related adverse events were reported, indicating a favorable safety profile for the nVNS treatment [3] - The findings are particularly relevant for the U.S. military, where 1-2% of service members experience mild TBI annually [2] Company Overview - electroCore is a commercial-stage bioelectronic technology company focused on improving health through innovative non-invasive technologies [5] - The company's leading products include gammaCore nVNS and Quell neurostimulator, which treat chronic pain syndromes [5]

Core Insights - electroCore, Inc. announced that its product gammaCore™ Sapphire (nVNS) has been included in a long-term reimbursement policy by the National Institute for Health and Disability Insurance (RIZIV / INAMI) in Belgium, effective October 1, 2025 [1][2] - The reimbursement policy allows coverage for gammaCore Sapphire to treat patients with cluster headaches, based on strong clinical evidence supporting its efficacy and cost-effectiveness, thus ensuring broader access for Belgian patients [2][3] Company and Product Details - electroCore is a commercial-stage bioelectronic medicine and wellness company focused on improving health through innovative non-invasive technologies, with gammaCore and Quell neurostimulator as its leading products [5] - The company emphasizes the significance of securing long-term reimbursement in Belgium as a major milestone for expanding access to its non-invasive therapies [4] Partnerships and Market Expansion - Silvert Medical, electroCore's distribution partner in Belgium, played a crucial role in securing the reimbursement by leveraging local expertise and provider relationships, and is committed to extending access to gammaCore in neighboring countries [3][4] - The partnership with Silvert Medical is highlighted as a key factor in bringing gammaCore to patients in Belgium and enhancing the company's market presence in Europe [4]

Company Leadership Changes - Peter Cuneo has departed from the Board of Directors of electroCore, Inc., with Thomas J. Errico, MD, elected as the new Chairman of the Board effective September 2, 2025 [1][2] - Cuneo will continue to serve as a strategic advisor to the company [1] - CEO Dan Goldberger expressed gratitude for Cuneo's contributions since 2020, highlighting his role in the company's turnaround [2] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through non-invasive bioelectronic technologies [3] - The company's leading products include gammaCore, a non-invasive vagus nerve stimulation device, and Quell neurostimulator, both aimed at treating chronic pain syndromes [3] - Additionally, electroCore markets handheld products like Truvaga and TAC-STIM, which utilize bioelectronic technologies for general wellness and human performance [3]